Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pranzatelli, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pranzatelli, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Reviews

Topical Review: Antidyskinetic Drug Therapy for Pediatric Movement Disorders

Michael R. Pranzatelli, MD

Department of Pediatrics, Neurology, and Pharmacology, The George Washington University, Washington, DC

The pharmacologic armamentarium used to treat dyskinesias in childhood is increasing. Anticonvulsant drugs as a class are still some of the broadest-spectrum antidyskinetic agents, probably because the class includes so many differently acting drugs or because dyskinesias are manifestations of subcortical electrical events. This group is enhanced by recent developments in {gamma}-aminobutyric acid and glutamate receptor pharmacology, which promise new antidyskinetic drugs. Other drugs acting at receptors for monoamines (dopamine, norepinephrine, and serotonin), acetylcholine, opioids, or histamine may provide symptomatic improvement. Fewer pharmacotherapies address the underlying pathophysiology of movement disorders. Of these, drugs or biologicals for immunomodulation are the most developed, but the group also includes antioxidants, cofactors, metabolic inhibitors, and chelators. There is potential for drugs that block the neurotoxic effects of glutamate to treat movement disorders and reverse or prevent brain injury. Peripheral blockade of focal dyskinesias through botulinum toxin offers a useful alternative to drugs in some patients. (J Child Neurol 1996;11:355-369).

Journal of Child Neurology, Vol. 11, No. 5, 355-369 (1996)
DOI: 10.1177/088307389601100503
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Child NeurolHome page
Y. Awaad, H. Tayem, A. Elgamal, and M. F. Coyne
Treatment of Childhood Myoclonus With Botulinum Toxin Type A
J Child Neurol, December 1, 1999; 14(12): 781 - 786.
[Abstract] [PDF]

Home page
 Neurorehabil Neural RepairHome page
C. Green, C. Proch, and S. E. Gara
Review Article : The Changing Face of Cerebral Palsy: A Review of the Disorder and Its Treatment
Neurorehabil Neural Repair, January 1, 1997; 11(4): 245 - 253.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
M. R. Pranzatelli
Oral Pharmacotherapy for the Movement Disorders of Cerebral Palsy
J Child Neurol, November 1, 1996; 11(1_suppl): S13 - S22.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
K. J. Bharucha
Pediatric Movement Disorders: Newer Therapeutic Strategies
J Child Neurol, September 1, 1996; 11(5): 353 - 354.
[PDF]